Protara Therapeutics Inc Stock Price, News & Analysis

Protara Therapeutics (Nasdaq: TARA) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A prerecorded presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET. Interested parties can access the presentation via the Events and Presentations section of Protara's website. Protara is focused on developing transformative therapies for cancer and rare diseases, including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.

Protara Therapeutics (Nasdaq: TARA) reported significant progress in its Phase 1 ADVANCED-1 study of TARA-002 for non-muscle invasive bladder cancer. As of June 30, 2022, the company holds a robust cash position of $112.8 million, sufficient to fund operations into mid-2024. R&D expenses decreased to $3.1 million, while general and administrative expenses fell to $5.6 million, leading to a reduced net loss of $8.5 million or $0.80 per share. Protara is also advancing TARA-002's development for lymphatic malformations and continues its study on IV Choline Chloride for intestinal failure.

Protara Therapeutics (TARA) announced that its Chief Financial Officer, Blaine Davis, will leave the company on July 15, 2022, to pursue other opportunities. His departure is not linked to the company's operations or financial reporting. As of March 31, 2022, Protara had cash and investments of $119 million, expected to fund operations into mid-2024. CEO Jesse Shefferman acknowledged Davis's contributions, highlighting the strength of the finance and operational teams. Protara focuses on developing transformative therapies, including TARA-002 for bladder cancer and lymphatic malformations.

Protara Therapeutics, Inc. (Nasdaq: TARA) announced plans to present a Trials in Progress poster on TARA-002 at the American Society of Clinical Oncology Annual Meeting from June 3-7, 2022. The ADVANCED-1 Phase 1 trial aims to evaluate TARA-002, an investigational immunopotentiator for non-muscle invasive bladder cancer (NMIBC). The trial is designed to assess the safety and preliminary anti-tumor activity of TARA-002 in treatment-naïve and experienced patients. Approximately 65,000 NMIBC cases are diagnosed annually in the U.S., emphasizing the need for new treatment options.

Protara Therapeutics, Inc. (Nasdaq: TARA) has announced its participation in the H.C. Wainwright Global Investment Conference from May 23 to May 26, 2022. Their prerecorded presentation will be available on May 24, 2022, at 7:00 a.m. ET. Interested viewers can access it via the Events and Presentations section of Protara's website, where it will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for intestinal failure-related liver disease.

Protara Therapeutics (Nasdaq: TARA) announced positive results from a retrospective analysis of OK-432, the basis for its investigational therapy TARA-002, targeting lymphatic malformations (LMs). Presented at the ISSVA World Congress 2022, the analysis involved 246 patients, showing approximately 69% clinical success in immediate treatment groups versus 7.5% in delayed groups. Serious adverse events were rare, with a favorable safety profile noted. These findings bolster the potential for TARA-002 to provide a much-needed FDA-approved treatment for LMs.

Protara Therapeutics (Nasdaq: TARA) announced dosing has begun in the Phase 1 ADVANCED-1 study of TARA-002 for non-muscle invasive bladder cancer (NMIBC). The company reported cash and investments of $119 million as of March 31, 2022, allowing funding through mid-2024. The Phase 2 trial for TARA-002 in lymphatic malformations is also planned following guidance from the FDA. Financially, R&D expenses decreased to $5.3 million from $7.0 million year-over-year, while the net loss narrowed to $10.8 million, or $0.96 per share.

Protara Therapeutics (Nasdaq: TARA) announced the dosing of the first patient in its Phase 1 clinical trial, ADVANCED-1, investigating TARA-002 for non-muscle invasive bladder cancer (NMIBC). This trial targets treatment-naïve and experienced patients with high-grade tumors. The primary goal is to evaluate TARA-002's safety and anti-tumor activity, setting the stage for a potential Phase 2 study. NMIBC accounts for 80% of bladder cancer cases, with a pressing need for effective treatment options.

Protara Therapeutics (TARA) has commenced a Phase 1 clinical trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC), following FDA IND clearance in October 2021. The company reported a strong cash position of $130.7M as of December 31, 2021, expected to fund operations into mid-2024. Research and development expenses rose to $21.1M for 2021, up from $12.0M the previous year. Protara registered a net loss of $10.2M in Q4 2021, compared to $8.8M in Q4 2020, with total net losses of $47.3M for 2021.